Eli Lilly and Co. (NYSE:LLY): Closing price $54.16
On Wednesday, Eli Lilly announced that 31 abstracts in all will be presented at the 49th European Association for the Study of Diabetes Annual Meeting in Barcelona, September 23 through 27. Through seven presentations, Lilly will share Phase III data for dulaglutide, which is its investigational GLP-1 receptor agonist, and Phase II data for LY2605541, its investigational novel basal insulin analog. Besides that, 17 abstracts will be presented by Boehringer Ingelheim on behalf of the Alliance with Lilly. Additionally, Lilly will present seven more abstracts, including research from its early-stage pipeline.
AstraZeneca Group plc. (NYSE:AZN): Closing price $52.08
AstraZeneca said Wednesday that the FDA has accepted for review a new drug application for Epanova, its investigational compound for the treatment for patients suffering from severe hypertriglyceridaemia. The NDA submission for Epanova was filed by the firm’s Omthera Pharmaceuticals subsidiary.
Prima BioMed Ltd. (NASDAQ:PBMD): Closing price $1.61
Prima BioMed has announced top-line analysis of the CAN-003 phase 2 study of CVac for treatment of epithelial ovarian cancer patients in first or second remission. Results show that CVac was mostly well tolerated, with no Serious Adverse Events considered linked with protocol therapy. The majority of non-Serious Adverse Events were considered mild and transient in nature. Though variable, immune monitoring data imply that CVac induces a T cell response which may be beneficial for patients having ovarian cancer. No evidence was indicated of a humoral (or antibody) response after CVac administration, which is also thought a positive signal.
Atossa Genetics, Inc. (NASDAQ:ATOS): Closing price $6.00
Atossa announced Wednesday that it has reached a nationwide distribution accord with McKesson Medical-Surgical through which to sell and distribute Atossa’s MASCT device and patient collection kits. The MASCT device is employed in OB/GYN, primary care, and women’s clinics to perform a non-invasive collection of breast fluid. The specimens are analyzed at the National Reference Laboratory for Breast Health, a subsidiary of Atossa, with the ForeCYTE Breast Health Test, which estimates a woman’s future risk of breast cancer.